ELUCIDATE the rationale behind early, individualized treatment of active MS disease
|
|
|
|
|
|
CONSTRUCT a risk/benefit analysis across current, newly approved and emerging MS therapies based on an understanding of MOAs, effects, safety and efficacy to in order to better individualize a patient’s treatment plan
|
|
|
|
|
|
APPLY evidence-based strategies for educating and counseling MS patients about pharmacological options and lifestyle approaches to improving health-related quality of life
|
|
|
|
|
|
IMPLEMENT a multidisciplinary treatment strategy involving methods for effective shared decision-making about MS DMTs
|
|
|
|
|
|